Director, Transplantation and Cellular Therapy Fellowship Program
Director, FACS Laboratory
Co-Director, Transplantation and Cellular Therapy Laboratory
Attending Physician; Hematology, Oncology and Blood and Marrow Transplantation
Investigator, Hematology-Oncology

Associate Professor of Clinical Pediatrics; Keck School of Medicine of USC
  • Summary
  • Publications
  • Research
  • Media
  • Locations

Dr Abdel-Azim is currently a principal and a co-principal investigator on several investigator-initiated and multi-center studies. He has authored numerous peer-reviewed journal articles and book chapters. His lab research is mainly focused on acute leukemia and flow image analysis.

Clinical Interests

 Dr. Abdel-Azim is an expert in blood and marrow transplantation, cellular and immunotherapy for a wide variety of cancers, bone marrow disorders, and genetic and non-malignant diseases. He also has special expertise in laboratory assessment for minimal residual disease in blood cancers and immune recovery after blood and marrow transplantation. His research interests include infections in immune compromised host, reduction of transplant-associated complications, treatment of graft vs host disease, and use of cell therapy for treatment of malignant and non-malignant diseases.



Medical School: 

Cairo University School of Medicine, Cairo, Egypt MD; Cairo University School of Medicine, Cairo, Egypt MS


New York Medical College (Metropolitan Program), New York/Valhalla, NY


New York Medical College (Metropolitan Program), New York/Valhalla, NY


Hematology/Oncology: Children's Hospital Los Angeles, Los Angeles, CA Blood and Marrow Transplantation: Children's Hospital Los Angeles, Los Angeles, CA



Dr Abdel-Azim is a board-certified physician in Hematology/Oncology and General Practice.

Professional Memberships: 



Top doctors, Pasadena Magazine, Southern California Super Doctors


Abdel-Azim H, Mahadeo KM, Zhao Q, Khazal S, Kohn DB, Crooks GM, Shah AJ, Kapoor N. Unrelated donor Hematopoietic Stem Cell Transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. American Journal of Hematology, 2015

George AA, Fei F, Paz H, Kirzner J, Kim Y, Heisterkamp N, Abdel-Azim H.

Phosphoflow-based evaluation of MEK inhibitors as small-molecule therapeutics for B-cell precursor acute lymphoblastic leukemia. PLOS1, 2015

Parekh CP, Gaynon PS, Abdel-Azim H. End of induction minimal residual disease alone is not a useful determinant for risk stratified therapy in pediatric T-cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2015

Fei F, Lim M, George AA, Kirzner J, Lee D, Seeger R, Groffen J, Abdel-Azim H*, Heisterkamp N*  [^co-senior authorship]. Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells. Leukemia, 2014.

Orgel, E, Tucci J, Alhushki W, Malvar J, Sposto R, Fu CH, Freyer DR, Abdel-Azim H*, Mittelman SD* [*co-senior authorship with equal contribution]. Obesity Is Associated with Residual Leukemia Following Induction Therapy for Childhood B-Precursor Acute Lymphoblastic Leukemia. Blood, 2014.

Quan Zhao, Kris Michael Mahadeo, Neena Kapoor, Hisham Abdel-Azim. Improved outcomes associated with Hematopoietic Stem Cell Transplantation for patients with juvenile myelomonocytic leukemia. Blood, 2015

Research Interests: 
  • Minimal residual disease in hematological malignancies in children
  • Use of cell and immune therapy for treatment of acute leukemia in children
  • Immunophenotypic and functional analysis of leukemic blasts and human hematopoietic stem and progenitor cells
  • Bone Marrow Transplantation for hemoglobinopathies and genetic diseases


Bone Marrow Transplant

Children's Hospital Los Angeles

4650 Sunset Blvd.
MS #62
Los Angeles, CA 90027
Phone: 323-361-4624Office
Fax: 323-361-8068Fax